|
WO1988008854A1
(en)
|
1987-05-06 |
1988-11-17 |
Egbert Oosterwijk |
Monoclonal antibodies to renal cell carcinoma
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
WO1989006544A1
(en)
|
1988-01-15 |
1989-07-27 |
Centocor, Inc. |
Heteroligating antibodies and therapeutic uses thereof
|
|
EP0557300B1
(en)
|
1990-10-29 |
1997-11-19 |
Chiron Corporation |
Bispecific antibodies, method of production, and uses thereof
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
US6036955A
(en)
|
1992-03-05 |
2000-03-14 |
The Scripps Research Institute |
Kits and methods for the specific coagulation of vasculature
|
|
EP0627940B1
(en)
|
1992-03-05 |
2003-05-07 |
Board of Regents, The University of Texas System |
Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
|
|
US5660827A
(en)
|
1992-03-05 |
1997-08-26 |
Board Of Regents, The University Of Texas System |
Antibodies that bind to endoglin
|
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
|
US5622701A
(en)
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
DE69636015T2
(de)
|
1995-05-03 |
2007-01-04 |
Bioenhancementsments Ltd. |
Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
|
|
DE19531346A1
(de)
|
1995-08-25 |
1997-02-27 |
Gsf Forschungszentrum Umwelt |
Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
DK1071752T3
(da)
|
1998-04-21 |
2003-10-20 |
Micromet Ag |
CD19xCD3-specifikke polypeptider og anvendelsen deraf
|
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
|
DE69936927T2
(de)
|
1998-10-21 |
2008-05-15 |
Altor Bioscience Corp., Miramar |
Polyspezifische bindemoleküle und deren verwendung
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US20040038339A1
(en)
|
2000-03-24 |
2004-02-26 |
Peter Kufer |
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
|
|
JP2004511430A
(ja)
|
2000-05-24 |
2004-04-15 |
イムクローン システムズ インコーポレイティド |
二重特異性免疫グロブリン様抗原結合蛋白および製造方法
|
|
US20040115198A1
(en)
|
2001-02-28 |
2004-06-17 |
Fred Hutchinson Cancer Research Center |
Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
|
|
US20030095965A1
(en)
|
2001-05-02 |
2003-05-22 |
Katrien Van Beneden |
Antibodies to Ly49E and CD94/NKG2 receptors
|
|
US20020193569A1
(en)
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
DE10156482A1
(de)
|
2001-11-12 |
2003-05-28 |
Gundram Jung |
Bispezifisches Antikörper-Molekül
|
|
CA2496419A1
(en)
|
2002-08-19 |
2004-02-26 |
Abgenix, Inc. |
Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
DE10261223A1
(de)
|
2002-12-20 |
2004-07-08 |
MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH |
Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
|
|
US20060235201A1
(en)
|
2003-02-06 |
2006-10-19 |
Roman Kischel |
Enduring T cell response
|
|
US7666417B2
(en)
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
|
CA2523716C
(en)
|
2003-05-31 |
2014-11-25 |
Micromet Ag |
Human anti-human cd3 binding molecules
|
|
JP2008501621A
(ja)
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
|
|
KR101420344B1
(ko)
|
2003-07-02 |
2014-07-16 |
위니베르시따 디 제노바 |
Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및 치료에서의 그 사용 방법
|
|
EP2292264A3
(en)
|
2003-07-24 |
2012-12-19 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
JP4948174B2
(ja)
|
2003-10-16 |
2012-06-06 |
マイクロメット アクツィエン ゲゼルシャフト |
多重特異的脱免疫ｃｄ３−結合物質
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
US20110020273A1
(en)
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
ZA200606410B
(en)
|
2004-02-16 |
2007-12-27 |
Micromet Ag |
Less immunogenic binding molecules
|
|
WO2005105849A1
(en)
|
2004-04-30 |
2005-11-10 |
Innate Pharma |
Compositions and methods for treating proliferative disorders such as nk-type ldgl
|
|
EA010374B1
(ru)
|
2004-07-16 |
2008-08-29 |
Микромет Аг |
Полипептиды с повышенной экспрессией
|
|
KR20110050567A
(ko)
|
2004-07-22 |
2011-05-13 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
MX2007003910A
(es)
|
2004-10-01 |
2007-06-07 |
Avidex Ltd |
Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
|
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
US20070071759A1
(en)
|
2005-06-29 |
2007-03-29 |
University Of Miami |
Antibody-immune cell ligand fusion protein for cancer therapy
|
|
WO2007022520A2
(en)
|
2005-08-19 |
2007-02-22 |
Cerus Corporation |
Antibody-mediated enhancement of immune response
|
|
PE20071101A1
(es)
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
JP5419067B2
(ja)
|
2005-10-14 |
2014-02-19 |
イナート・ファルマ・ソシエテ・アノニム |
増殖性障害を処置するための組成物および方法
|
|
EP1945771A1
(en)
|
2005-10-28 |
2008-07-23 |
Novo Nordisk A/S |
Fusion proteins that bind effector lymphocytes and target cells
|
|
EP1945674A2
(en)
|
2005-11-03 |
2008-07-23 |
Genentech, Inc. |
Therapeutic anti-her2 antibody fusion polypeptides
|
|
JP2009514528A
(ja)
|
2005-11-03 |
2009-04-09 |
フレッド ハッチンソン キャンサー リサーチ センター |
Ｎｋｇ２ｄ陽性ｃｄ４＋細胞による免疫応答の負の免疫調節法
|
|
US8007796B2
(en)
|
2005-12-16 |
2011-08-30 |
Micromet Ag |
Means and methods for the treatment of tumorous diseases
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
EP2418223A3
(en)
*
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
CA2663388C
(en)
|
2006-09-07 |
2017-01-17 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
|
|
EP1900752A1
(en)
|
2006-09-15 |
2008-03-19 |
DOMPE' pha.r.ma s.p.a. |
Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
|
|
KR20100021601A
(ko)
|
2007-05-14 |
2010-02-25 |
바이오겐 아이덱 엠에이 인코포레이티드 |
단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
|
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
|
ES2320076B2
(es)
|
2007-07-11 |
2010-01-26 |
La Morella Nuts, S.A. |
Procedimiento en continuo de fabricacion de productos alimenticios.
|
|
WO2009013543A2
(en)
|
2007-07-25 |
2009-01-29 |
Astrazeneca Ab |
Targeted binging agents directed to kdr and uses thereof - 035
|
|
CN103298935A
(zh)
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
JP5933894B2
(ja)
|
2007-09-14 |
2016-06-15 |
アディマブ， エルエルシー |
合理的に設計された、合成抗体ライブラリおよびその使用
|
|
JP5591712B2
(ja)
|
2007-12-14 |
2014-09-17 |
ノボ・ノルデイスク・エー／エス |
ヒトｎｋｇ２ｄに対する抗体とその使用
|
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
|
KR20100106590A
(ko)
|
2008-01-22 |
2010-10-01 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Ｒｏｎ 항체 및 이들의 용도
|
|
AR072000A1
(es)
|
2008-06-03 |
2010-07-28 |
Abbott Lab |
Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
|
|
US8067339B2
(en)
|
2008-07-09 |
2011-11-29 |
Merck Sharp & Dohme Corp. |
Surface display of whole antibodies in eukaryotes
|
|
WO2010017103A2
(en)
*
|
2008-08-04 |
2010-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Fully human anti-human nkg2d monoclonal antibodies
|
|
US20100124764A1
(en)
|
2008-09-26 |
2010-05-20 |
Wyeth |
Single chain antibody library design
|
|
DK2356270T3
(da)
|
2008-11-07 |
2016-12-12 |
Fabrus Llc |
Kombinatoriske antistofbiblioteker og anvendelser deraf
|
|
US10865233B2
(en)
|
2008-12-18 |
2020-12-15 |
Dana-Farber Cancer Institute, Inc. |
NKG2D-fc for immunotherapy
|
|
SG172254A1
(en)
|
2008-12-19 |
2011-07-28 |
Macrogenics Inc |
Covalent diabodies and uses thereof
|
|
MX2011010166A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
|
WO2010132697A2
(en)
|
2009-05-13 |
2010-11-18 |
Genzyme Corporation |
Methods and compositions for treatment
|
|
GB0909904D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Product
|
|
WO2010144295A1
(en)
|
2009-06-09 |
2010-12-16 |
University Of Miami |
Aptamer-targeted costimulatory ligand aptamer
|
|
SG177560A1
(en)
|
2009-07-06 |
2012-03-29 |
Hoffmann La Roche |
Bi-specific digoxigenin binding antibodies
|
|
UY32808A
(es)
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2476752A4
(en)
|
2009-09-11 |
2013-04-03 |
Takara Bio Inc |
PROCESS FOR THE PRODUCTION OF NATURAL KILLER CELLS
|
|
DE102009045006A1
(de)
|
2009-09-25 |
2011-04-14 |
Technische Universität Dresden |
Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
|
|
NZ598732A
(en)
|
2009-10-27 |
2014-09-26 |
Amgen Res Munich Gmbh |
Dosage regimen for administering a cd19xcd3 bispecific antibody
|
|
WO2011057124A1
(en)
|
2009-11-06 |
2011-05-12 |
Transtarget, Inc. |
Polyclonal bispecific antibody compositions and method of use
|
|
EP2332994A1
(en)
|
2009-12-09 |
2011-06-15 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Trispecific therapeutics against acute myeloid leukaemia
|
|
AU2010330794A1
(en)
|
2009-12-18 |
2012-06-21 |
Amgen Inc. |
Wise binding agents and epitopes
|
|
US8796420B2
(en)
|
2009-12-31 |
2014-08-05 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
|
US8658765B2
(en)
|
2009-12-31 |
2014-02-25 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
|
WO2011085178A1
(en)
|
2010-01-11 |
2011-07-14 |
Trustees Of Dartmouth College |
Monomeric bi-specific fusion protein
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
PL2560993T3
(pl)
|
2010-04-20 |
2024-11-04 |
Genmab A/S |
Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
|
|
US9637557B2
(en)
|
2010-04-23 |
2017-05-02 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
KR101834026B1
(ko)
|
2010-06-19 |
2018-03-02 |
메모리얼 슬로안-케터링 캔서 센터 |
항-ｇｄ2 항체
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
DE102010039018B4
(de)
|
2010-08-06 |
2013-02-28 |
Technische Universität Dresden |
Anti-La Antikörper und ihre Anwendung zum Immunotargeting
|
|
WO2012020096A1
(en)
|
2010-08-13 |
2012-02-16 |
Medimmune Limited |
Monomeric polypeptides comprising variant fc regions and methods of use
|
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
RU2013115927A
(ru)
|
2010-09-10 |
2014-10-20 |
Апексиджен, Инк. |
АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
WO2012061558A2
(en)
|
2010-11-04 |
2012-05-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
CA2817015A1
(en)
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
|
JP6013915B2
(ja)
|
2010-11-17 |
2016-10-25 |
中外製薬株式会社 |
血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
|
|
US20120195900A1
(en)
|
2010-12-22 |
2012-08-02 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
|
EP3604330A1
(en)
|
2011-02-25 |
2020-02-05 |
Chugai Seiyaku Kabushiki Kaisha |
Fcgammariib-specific fc antibody
|
|
ES2668895T3
(es)
|
2011-03-16 |
2018-05-23 |
Amgen Inc. |
Variantes de Fc
|
|
US9683052B2
(en)
|
2011-03-25 |
2017-06-20 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
WO2012162068A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
|
US20140234342A1
(en)
|
2011-06-21 |
2014-08-21 |
Innate Pharma |
Nkp46-mediated nk cell tuning
|
|
DE102011118022B4
(de)
|
2011-06-30 |
2018-01-18 |
Gemoab Monoclonals Gmbh |
Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
|
|
US9890218B2
(en)
|
2011-06-30 |
2018-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
US8790651B2
(en)
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
WO2013013700A1
(en)
|
2011-07-22 |
2013-01-31 |
Affimed Therapeutics Ag |
Multivalent antigen-binding fv molecule
|
|
WO2013036799A2
(en)
|
2011-09-09 |
2013-03-14 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving nkg2d inhibitors and cancer
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
CN113061993A
(zh)
|
2011-09-30 |
2021-07-02 |
中外制药株式会社 |
离子浓度依赖性结合分子文库
|
|
EP2794658B1
(en)
|
2011-12-19 |
2017-03-15 |
Synimmune GmbH |
Bispecific antibody molecule
|
|
CA2863714C
(en)
|
2012-02-08 |
2022-07-05 |
Igm Biosciences, Inc. |
Cdim binding proteins and uses thereof
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
US9029510B2
(en)
|
2012-03-30 |
2015-05-12 |
Sorrento Therapeutics, Inc. |
Fully human antibodies that bind to VEGFR2 and methods of use thereof
|
|
DK2838917T3
(da)
|
2012-04-20 |
2019-08-26 |
Merus Nv |
Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
|
|
US9163090B2
(en)
|
2012-05-07 |
2015-10-20 |
Cellerant Therapeutics, Inc. |
Antibodies specific for CLL-1
|
|
SG10202006507XA
(en)
|
2012-05-30 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Target-tissue-specific antigen-binding molecule
|
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたＦｃ領域を含む抗原結合分子
|
|
EP2863946A4
(en)
|
2012-06-21 |
2016-04-13 |
Sorrento Therapeutics Inc |
ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET
|
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
|
US20140154253A1
(en)
|
2012-07-13 |
2014-06-05 |
Zymeworks Inc. |
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
|
|
AU2013293092A1
(en)
|
2012-07-23 |
2015-02-26 |
Zymeworks Inc. |
Immunoglobulin constructs comprising selective pairing of the light and heavy chains
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
EP2885002A4
(en)
|
2012-08-14 |
2016-04-20 |
Ibc Pharmaceuticals Inc |
BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
|
|
HRP20181717T1
(hr)
|
2012-09-27 |
2018-12-28 |
Merus N.V. |
Bispecifična igg protutijela kao aktivatori t stanice
|
|
CN112079929A
(zh)
|
2012-11-21 |
2020-12-15 |
武汉友芝友生物制药有限公司 |
双特异性抗体
|
|
EP2927321B1
(en)
|
2012-11-27 |
2021-02-17 |
Ajou University Industry-Academic Cooperation Foundation |
Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
|
EP2934577A1
(en)
|
2012-12-19 |
2015-10-28 |
Adimab, LLC |
Multivalent antibody analogs, and methods of their preparation and use
|
|
KR20240123420A
(ko)
|
2013-01-10 |
2024-08-13 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
ES2667420T3
(es)
|
2013-02-05 |
2018-05-10 |
Engmab Sàrl |
Anticuerpos biespecíficos contra cd3epsilon y bcma
|
|
HK1218930A1
(zh)
|
2013-02-08 |
2017-03-17 |
Abbvie Stemcentrx Llc |
新型多特异性结构
|
|
UA119320C2
(uk)
|
2013-02-26 |
2019-06-10 |
Рош Глікарт Аг |
Активуюча т-клітини біспецифічна антигензв'язувальна молекула
|
|
EP2968520B1
(en)
|
2013-03-14 |
2021-05-12 |
MacroGenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2970435B1
(en)
|
2013-03-15 |
2020-08-12 |
Eli Lilly and Company |
Methods for producing fabs and bi-specific antibodies
|
|
JP6482525B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
高親和性抗ｇｄ２抗体
|
|
PL3587448T3
(pl)
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
|
US20140323315A1
(en)
|
2013-04-29 |
2014-10-30 |
Adimab, Llc |
Polyspecificity reagents, methods for their preparation and use
|
|
EP2994490A1
(en)
|
2013-05-10 |
2016-03-16 |
Numab AG |
Bispecific constructs and their use in the treatment of various diseases
|
|
EP3008093A1
(en)
|
2013-06-11 |
2016-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
|
|
EP3022229A1
(en)
|
2013-07-15 |
2016-05-25 |
Novo Nordisk A/S |
Antibodies that bind urokinase plasminogen activator
|
|
AU2014290069B2
(en)
|
2013-07-16 |
2019-01-03 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
|
DK3406633T3
(da)
|
2013-07-25 |
2022-03-28 |
Cytomx Therapeutics Inc |
Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
|
|
GB2518221A
(en)
|
2013-09-16 |
2015-03-18 |
Sergej Michailovic Kiprijanov |
Tetravalent antigen-binding protein molecule
|
|
CN111606998B
(zh)
|
2013-09-16 |
2024-05-24 |
健康与环境慕尼黑德国研究中心赫姆霍茨中心（有限责任公司） |
用于治疗hbv感染和相关病症的双或多特异性多肽
|
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
|
JP6553069B2
(ja)
|
2013-11-07 |
2019-07-31 |
メモリアル スローン ケタリング キャンサー センター |
抗ｗｔ１／ｈｌａ二重特異性抗体
|
|
DE102013019352A1
(de)
|
2013-11-13 |
2015-09-17 |
Elke Pogge Von Strandmann |
Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
|
|
PT3074424T
(pt)
|
2013-11-27 |
2025-05-29 |
Zymeworks Bc Inc |
Construções de ligação a antigénio biespecíficas direcionadas a her2
|
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
|
WO2015095412A1
(en)
|
2013-12-19 |
2015-06-25 |
Zhong Wang |
Bispecific antibody with two single-domain antigen-binding fragments
|
|
CA2925677A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
JP7325166B2
(ja)
|
2013-12-20 |
2023-08-14 |
ジェネンテック， インコーポレイテッド |
二重特異性抗体
|
|
AU2014373593B2
(en)
|
2013-12-23 |
2020-07-16 |
Zymeworks Bc Inc. |
Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
|
|
NZ720353A
(en)
|
2013-12-30 |
2019-12-20 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
WO2015109131A2
(en)
|
2014-01-15 |
2015-07-23 |
Zymeworks Inc. |
Bi-specific cd3 and cd19 antigen-binding constructs
|
|
US20170066827A1
(en)
|
2014-03-05 |
2017-03-09 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
DK3126384T3
(da)
|
2014-04-01 |
2021-01-18 |
Adimab Llc |
Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
KR102380402B1
(ko)
|
2014-04-03 |
2022-03-31 |
아이쥐엠 바이오사이언스 인코포레이티드 |
변형된 j-사슬
|
|
ES2819863T3
(es)
|
2014-04-11 |
2021-04-19 |
Medimmune Llc |
Anticuerpos contra HER2 biespecíficos
|
|
EP2930188A1
(en)
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
|
EP2942629A1
(en)
|
2014-05-08 |
2015-11-11 |
Universität Würzburg |
Predictive markers for successful cancer immunotherapy
|
|
TWI742423B
(zh)
|
2014-05-29 |
2021-10-11 |
美商宏觀基因股份有限公司 |
特異性結合多種癌症抗原的三特異性結合分子和其使用方法
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
WO2015197598A2
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
WO2015197582A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Monomeric multispecific antigen binding proteins
|
|
US10519234B2
(en)
|
2014-06-27 |
2019-12-31 |
Innate Pharma |
NKp46 binding proteins
|
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
|
US9777073B2
(en)
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
CN106999556B
(zh)
|
2014-07-21 |
2021-07-30 |
武汉友芝友生物制药有限公司 |
细胞因子诱导的杀伤细胞的双特异性抗体介导的癌症治疗
|
|
JP6390239B2
(ja)
|
2014-07-25 |
2018-09-19 |
富士ゼロックス株式会社 |
情報処理装置、及びプログラム
|
|
EP2985294A1
(en)
|
2014-08-14 |
2016-02-17 |
Deutsches Krebsforschungszentrum |
Recombinant antibody molecule and its use for target cell restricted T cell activation
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
RU2017105425A
(ru)
|
2014-08-28 |
2018-09-28 |
Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк |
Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
|
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
CN107074961A
(zh)
|
2014-11-03 |
2017-08-18 |
默克专利股份公司 |
用于生成双特异性鲨鱼可变抗体结构域的方法及其用途
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
CA3204990A1
(en)
|
2014-12-05 |
2016-06-09 |
Xyphos Biosciences Inc. |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
|
|
CA2970255A1
(en)
|
2014-12-17 |
2016-06-23 |
Intrexon Corporation |
Intercalated single-chain variable fragments
|
|
US10941207B2
(en)
|
2014-12-19 |
2021-03-09 |
Chiome Bioscience, Inc |
Fusion protein comprising three binding domains to 5T4 and CD3
|
|
IL253180B2
(en)
|
2015-01-02 |
2023-04-01 |
Dyax Corp |
Bispecific antibodies against plasma kallikrein and factor xii
|
|
US20180318417A1
(en)
|
2015-01-14 |
2018-11-08 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
AR100680A1
(es)
|
2015-01-26 |
2016-10-26 |
Macrogenics Inc |
Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
|
|
KR102606190B1
(ko)
*
|
2015-02-20 |
2023-11-23 |
오하이오 스테이트 이노베이션 파운데이션 |
Nkg2d 및 종양 연관 항원에 대해 유도된 이가 항체
|
|
MA41613A
(fr)
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
WO2016142768A1
(en)
|
2015-03-10 |
2016-09-15 |
Eureka Therapeutics, Inc. |
Ror2 antibody
|
|
WO2016146702A1
(en)
|
2015-03-16 |
2016-09-22 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Trispecific binding molecules for treating hbv infection and associated conditions
|
|
RU2021124437A
(ru)
|
2015-04-03 |
2021-09-29 |
Еурека Терапьютикс, Инк. |
Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
|
|
PH12017501834B1
(en)
|
2015-04-06 |
2024-01-17 |
Arcellx Inc |
De novo binding domain containing polypeptides and uses thereof
|
|
HUE057432T2
(hu)
|
2015-04-07 |
2022-05-28 |
Alector Llc |
Anti-sortilin antitestek és ezek alkalmazási módjai
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
EP3297671A4
(en)
|
2015-05-18 |
2019-02-06 |
Eureka Therapeutics, Inc. |
ANTI-ROR1 ANTIBODY
|
|
EP3095792A1
(en)
|
2015-05-19 |
2016-11-23 |
Klinikum rechts der Isar der Technischen Universität München |
T cell receptor with specificity for myeloperoxidase peptide and uses thereof
|
|
WO2016191305A1
(en)
|
2015-05-22 |
2016-12-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Btn3a ectodomain proteins and methods of use
|
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
|
SI3303394T1
(sl)
|
2015-05-29 |
2020-10-30 |
Agenus Inc. |
Protitelesa proti-CTLA-4 in postopki njihove uporabe
|
|
CN107708741A
(zh)
|
2015-06-12 |
2018-02-16 |
免疫医疗公司 |
用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
|
|
EP3307779A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
|
WO2016207278A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
|
AU2016284866B2
(en)
|
2015-06-23 |
2022-09-29 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
TN2017000543A1
(en)
|
2015-07-06 |
2019-04-12 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
WO2017011342A1
(en)
|
2015-07-10 |
2017-01-19 |
Abbvie Inc. |
Igm-or-ige-modified binding proteins and uses thereof
|
|
WO2017008169A1
(en)
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
|
EP3322449A1
(en)
|
2015-07-16 |
2018-05-23 |
Cellerant Therapeutics, Inc. |
Cysteine-substituted immunoglobulins
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
AU2016322934A1
(en)
|
2015-09-14 |
2018-04-12 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
|
|
MA43017A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
|
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
|
CN116003596A
(zh)
|
2015-10-29 |
2023-04-25 |
艾利妥 |
抗siglec-9抗体及其使用方法
|
|
US11197919B2
(en)
|
2015-11-04 |
2021-12-14 |
City Of Hope |
Chimeric antigen receptors targeting HER2
|
|
EP3373952A4
(en)
|
2015-11-10 |
2019-05-22 |
Fred Hutchinson Cancer Research Center |
NKG2D decoys
|
|
EP3374389A1
(en)
|
2015-11-13 |
2018-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
|
CN115925933A
(zh)
|
2015-12-28 |
2023-04-07 |
依奈特制药公司 |
NKp46结合蛋白的可变区
|
|
BR112018014368A2
(pt)
|
2016-01-13 |
2019-02-05 |
Compass Therapeutics Llc |
polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
UY37127A
(es)
|
2016-02-17 |
2017-08-31 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
US20190338013A1
(en)
|
2016-02-26 |
2019-11-07 |
Imunexus Pty Ltd |
Multi-Specific Molecules
|
|
CA3016563A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
KR20180135460A
(ko)
|
2016-04-15 |
2018-12-20 |
자임워크스 인코포레이티드 |
면역치료제를 표적으로 하는 다중-특이적 항원-결합 작제물
|
|
TWI781098B
(zh)
|
2016-04-15 |
2022-10-21 |
美商宏觀基因股份有限公司 |
新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
|
|
GB201610044D0
(en)
|
2016-06-08 |
2016-07-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
CN105906722B
(zh)
|
2016-06-24 |
2020-02-07 |
安徽未名细胞治疗有限公司 |
一种Her2特异性嵌合抗原受体及其应用
|
|
WO2018045090A1
(en)
|
2016-09-01 |
2018-03-08 |
Immunomab, Inc. |
Bispecific antibodies
|
|
WO2018071777A1
(en)
|
2016-10-14 |
2018-04-19 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｍｉｃ抗体及び使用方法
|
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
|
EP4491234A3
(en)
|
2017-02-08 |
2025-04-09 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
WO2018148447A1
(en)
|
2017-02-08 |
2018-08-16 |
Adimab, Llc |
Antibody heavy chain variable domains targeting the nkg2d receptor
|
|
CN110913902A
(zh)
|
2017-02-10 |
2020-03-24 |
蜻蜓疗法股份有限公司 |
结合psma、nkg2d和cd16的蛋白质
|
|
MA47465A
(fr)
|
2017-02-10 |
2019-12-18 |
Dragonfly Therapeutics Inc |
Protéines fixant le bcma, le nkg2d et le cd16
|
|
KR20190120783A
(ko)
|
2017-02-20 |
2019-10-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Gd2, nkg2d 및 cd16에 결합하는 단백질
|
|
CN110914305A
(zh)
|
2017-02-20 |
2020-03-24 |
蜻蜓疗法股份有限公司 |
结合cd123、nkg2d和cd16的蛋白质
|
|
BR112019017197A2
(pt)
|
2017-02-20 |
2020-04-14 |
Dragonfly Therapeutics, Inc. |
proteínas que se ligam a her2, nkg2d e cd16
|
|
JP2020510646A
(ja)
|
2017-02-20 |
2020-04-09 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
|
|
WO2018157147A1
(en)
|
2017-02-27 |
2018-08-30 |
Dragonfly Therapeutics, Inc. |
Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CA3064743A1
(en)
|
2017-05-23 |
2018-11-29 |
Dragonfly Therapeutics, Inc. |
A protein binding nkg2d, cd16 and ror1 or ror2
|
|
EP3630181A4
(en)
|
2017-05-23 |
2021-03-17 |
Dragonfly Therapeutics, Inc. |
NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN
|
|
CA3064714A1
(en)
|
2017-05-23 |
2018-11-29 |
Dragonfly Therapeutics, Inc. |
A protein binding nkg2d, cd16 and a tumor-associated antigen
|
|
JP2019014449A
(ja)
|
2017-07-10 |
2019-01-31 |
トヨタ自動車株式会社 |
車両用動力伝達装置
|
|
MX2020001257A
(es)
|
2017-07-31 |
2020-08-17 |
Dragonfly Therapeutics Inc |
Proteinas que se unen a nkg2d, cd16 y flt3.
|
|
KR20200037388A
(ko)
|
2017-08-16 |
2020-04-08 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질
|
|
IL311488A
(en)
|
2017-08-23 |
2024-05-01 |
Dragonfly Therapeutics Inc |
Proteins that bind D2NKG, 16CD, and tumor-associated antigen
|
|
EP3925976A1
(en)
|
2017-09-07 |
2021-12-22 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
|
CA3075857A1
(en)
|
2017-09-14 |
2019-03-21 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
|
|
AU2019218125B2
(en)
|
2018-02-08 |
2025-03-13 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
PE20220278A1
(es)
|
2018-02-08 |
2022-02-25 |
Dragonfly Therapeutics Inc |
Dominios variables de anticuerpos que se dirigen al receptor nkg2d
|
|
CA3091764A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting cd33, and use thereof
|
|
TW201942134A
(zh)
|
2018-02-20 |
2019-11-01 |
美商蜻蜓醫療公司 |
結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
|
|
WO2019195409A1
(en)
|
2018-04-03 |
2019-10-10 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
|
|
WO2019195408A1
(en)
|
2018-04-03 |
2019-10-10 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting dll3, and use thereof
|
|
JP2021523140A
(ja)
|
2018-05-07 |
2021-09-02 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合するタンパク質
|
|
MX2020012273A
(es)
|
2018-05-16 |
2021-04-28 |
Dragonfly Therapeutics Inc |
Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
|
|
EA202091977A1
(ru)
|
2018-05-28 |
2021-02-09 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
|
|
EA202190468A1
(ru)
|
2018-08-08 |
2021-07-06 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
|
|
KR20250112921A
(ko)
|
2018-08-08 |
2025-07-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
CN112789291A
(zh)
|
2018-08-08 |
2021-05-11 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
AU2019366956B2
(en)
|
2018-10-23 |
2025-10-30 |
Dragonfly Therapeutics, Inc. |
Heterodimeric Fc-fused proteins
|
|
JP2022520978A
(ja)
|
2019-02-18 |
2022-04-04 |
クーリエ セラピューティクス インコーポレイテッド |
オルソポックスウイルス主要組織適合性複合体（ｍｈｃ）クラスｉ様タンパク質（ｏｍｃｐ）と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質
|
|
MX2021015452A
(es)
|
2019-06-25 |
2022-02-11 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso.
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
CN118924895A
(zh)
|
2019-08-30 |
2024-11-12 |
蜻蜓疗法股份有限公司 |
用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
|
|
MX2022004291A
(es)
|
2019-10-15 |
2022-05-10 |
Dragonfly Therapeutics Inc |
Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos.
|
|
AR120223A1
(es)
|
2019-10-15 |
2022-02-02 |
Dragonfly Therapeutics Inc |
Proteínas que unen nkg2d, cd16 y flt3
|
|
WO2021216916A1
(en)
|
2020-04-22 |
2021-10-28 |
Dragonfly Therapeutics, Inc. |
Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
|
|
EP4146271A4
(en)
|
2020-05-06 |
2024-09-04 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
|
|
CN115697402A
(zh)
|
2020-05-06 |
2023-02-03 |
蜻蜓疗法股份有限公司 |
靶向clec12a的抗体及其用途
|
|
BR112023002116A2
(pt)
|
2020-08-05 |
2023-04-25 |
Dragonfly Therapeutics Inc |
Proteínas que se ligam a nkg2d, cd16 e egfr
|
|
KR20230042753A
(ko)
|
2020-08-05 |
2023-03-29 |
드래곤플라이 쎄라퓨틱스, 인크. |
Egfr을 표적화하는 항체 및 그의 용도
|
|
US12377144B2
(en)
|
2021-03-03 |
2025-08-05 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
|
|
CA3233246A1
(en)
|
2021-09-29 |
2023-04-06 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting baff-r and use thereof
|
|
KR20240087855A
(ko)
|
2021-09-29 |
2024-06-19 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 baff-r에 결합하는 단백질
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
US20230250176A1
(en)
|
2022-02-09 |
2023-08-10 |
Dragonfly Therapeutics, Inc. |
Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16
|
|
WO2023168384A2
(en)
|
2022-03-03 |
2023-09-07 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2
|